Answers are grounded in this paper and cite their sources.
Review summarizes advances in metal-free carbon monoxide prodrugs, highlighting key strategies to overcome delivery limitations for clinical gasotransmitter therapy.
Carbon monoxide is an important gasotransmitter in mammals, with pleiotropic therapeutic potential against a wide range of human diseases. However, clinical translation of CO is severely hampered by the lack of a reliable CO delivery form. The development of metal-free CO prodrugs is the key to resolving such delivery issues. Over the past three years, some new exciting progress has been made in this field. In this review, we highlight these advances and discuss related issues.
No takes yet. Share an insight, caveat, or question.
Min et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: